Chromocell Therapeutics (CHRO) News Today $1.90 +0.94 (+97.92%) Closing price 01/17/2025 04:00 PM EasternExtended Trading$2.02 +0.12 (+6.11%) As of 08:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on SuzetrigineDecember 20, 2024 | globenewswire.comChannel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block ModelDecember 18, 2024 | globenewswire.comChromocell Therapeutics Corp (CHRO)December 13, 2024 | investing.comChannel Therapeutics Corporation (CHRO)December 5, 2024 | finance.yahoo.comChromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program UpdatesNovember 23, 2024 | stockhouse.comChromocell Therapeutics Rebrands to Focus on Pain TreatmentsNovember 22, 2024 | markets.businessinsider.comChromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program UpdatesNovember 21, 2024 | markets.businessinsider.comChromocell Announces Name Change to “Channel Therapeutics Corporation†and Provides Therapeutic Program UpdatesNovember 21, 2024 | globenewswire.comChromocell Therapeutics Merges into Channel TherapeuticsNovember 20, 2024 | markets.businessinsider.comChromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical PainOctober 29, 2024 | globenewswire.comChromocell Announces Amendment to Stock Repurchase PlanOctober 24, 2024 | globenewswire.comChromocell to Participate in Life Sciences Investor Forum September 19thSeptember 16, 2024 | globenewswire.comChromocell Announces Stock Repurchase PlanAugust 7, 2024 | globenewswire.comChromocell to Participate in the Virtual Investor Lunch Break SeriesJuly 15, 2024 | globenewswire.comCHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024May 20, 2024 | investorplace.comChromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024May 13, 2024 | globenewswire.comChromocell Issues Letter to Stockholders from Chief Executive OfficerApril 9, 2024 | globenewswire.comChromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon ChandlerMarch 21, 2024 | globenewswire.comChromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023March 18, 2024 | globenewswire.comChromocell to Present at Sidoti Virtual Investor Conference March 13-14March 11, 2024 | globenewswire.comBenuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare SolutionsFebruary 27, 2024 | globenewswire.comChromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 MillionFebruary 21, 2024 | globenewswire.comChromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public OfferingFebruary 16, 2024 | globenewswire.com Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address CHRO Media Mentions By Week CHRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CHRO News Sentiment▼0.000.49▲Average Medical News Sentiment CHRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CHRO Articles This Week▼00▲CHRO Articles Average Week Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NextCure News Today Cara Therapeutics News Today Traws Pharma News Today Pulmatrix News Today Cocrystal Pharma News Today Tenax Therapeutics News Today Exicure News Today Athira Pharma News Today GeoVax Labs News Today MIRA Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CHRO) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
